RAM
DRUG

Readystate Asset Management’s Bright Minds Biosciences DRUG Stock Holding History

Readystate Asset Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,975
Closed -$365K – 450
2025
Q2 		$365K Buy
+13,975
New +$419K 0.01% 481

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Readystate Asset Management's DRUG Position: Q3 2025 in Review

Readystate Asset Management sold out of Bright Minds Biosciences (DRUG) in Q3 2025, closing a stake of 13,975 shares — an estimated $365K sold.

Readystate Asset Management first reported a position in DRUG in Q2 2025 and held it in 1 quarter. The position peaked at $365K in Q2 2025. 64 funds tracked by Wall St. Rank hold DRUG as of Q3 2025.

  • Readystate Asset Management reported no remaining Bright Minds Biosciences position as of Q3 2025 after selling out during the quarter.
  • Readystate Asset Management sold 13,975 Bright Minds Biosciences shares in Q3 2025, an estimated $365K.
  • Readystate Asset Management first reported a position in Bright Minds Biosciences in Q2 2025 and held it in 1 quarter.
  • Readystate Asset Management's Bright Minds Biosciences position peaked at $365K in Q2 2025.
  • 64 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2025.

Based on Readystate Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.